BCMA-Directed Bispecifics in Relapsed/Refractory Multiple Myeloma

home / case-based-digest / bcma-directed-bispecifics-in-relapsed-refractory-multiple-myeloma

A review of the use of bispecific antibodies directed at the BCMA target in relapsed/refractory multiple myeloma

Image of a man wearing a black t-shirt smiling in front of a blue background

How Do BCMA-Targeting Bispecific Antibodies Work?

Caleb Raine, PA-C
September 24th 2025

Caleb Raine, PA-C explains what BCMA is and why it is a common bispecific antibody target in multiple myeloma.

Headshot of a woman with black hair wearing a pearl necklace and a white blouse

Monitoring Severe Adverse Effects of Bispecifics in Multiple Myeloma

Lisa Hwa Christenson, APRN, DNP, CNP, FAPO
September 4th 2025

Lisa Hwa Christenson, DNP, CNP, FAPO, shares best practices for monitoring CRS and ICANS with BCMA bispecific antibodies in community oncology.

Image of a woman with wavy brown hair in front of a blue background

Why Step-Up Dose With Bispecific Antibodies?

Karolina Faysman, NP
September 3rd 2025

Karolina Faysman, NP, explains how step-up dosing is used to reduce CRS and ICANS with bispecific antibodies in multiple myeloma.

Lisa Hwa Christenson, APRN, DNP, CNP, FAPO

Transitioning to Community Care With Multiple Myeloma

Lisa Hwa Christenson, APRN, DNP, CNP, FAPO
August 28th 2025

Lisa Hwa Christenson, APRN, DNP, CNP, FAPO, outlines best practices for safely transitioning patients with multiple myeloma on bispecific antibodies to community care.

© 2025 MJH Life Sciences

All rights reserved.